CN106075128B - 一种含有积雪草的中药组合物及其应用 - Google Patents
一种含有积雪草的中药组合物及其应用 Download PDFInfo
- Publication number
- CN106075128B CN106075128B CN201610553522.3A CN201610553522A CN106075128B CN 106075128 B CN106075128 B CN 106075128B CN 201610553522 A CN201610553522 A CN 201610553522A CN 106075128 B CN106075128 B CN 106075128B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- centella
- drug
- cough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 241000167550 Centella Species 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 206010011224 Cough Diseases 0.000 claims abstract description 32
- 208000004880 Polyuria Diseases 0.000 claims abstract description 26
- 230000035619 diuresis Effects 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 20
- 235000013717 Houttuynia Nutrition 0.000 claims abstract description 18
- 241001646834 Mesona Species 0.000 claims abstract description 18
- 241001499733 Plantago asiatica Species 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 244000025254 Cannabis sativa Species 0.000 claims description 8
- 229940100688 oral solution Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 241001598107 Imperata Species 0.000 claims 2
- 235000013402 health food Nutrition 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 210000002700 urine Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 206010023126 Jaundice Diseases 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- 206010019345 Heat stroke Diseases 0.000 description 3
- 208000015817 Infant Nutrition disease Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 208000001786 gonorrhea Diseases 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 244000000053 intestinal parasite Species 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 244000146462 Centella asiatica Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 2
- 229940022757 asiaticoside Drugs 0.000 description 2
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241001415830 Bubo Species 0.000 description 1
- 241000288570 Chionochloa conspicua Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010011684 Cutaneous tuberculosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 241001113556 Elodea Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000007171 Imperata cylindrica Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241001571764 Lysimachia christinae Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 241000961970 Plantago depressa Species 0.000 description 1
- 241001646828 Platostoma chinense Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241000534017 Saururus chinensis Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000012642 Sexual Trauma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 235000021168 barbecue Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000016335 bubo Diseases 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 125000004395 glucoside group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种含有积雪草的中药组合物及其应用,其配方由以下重量比的中药材组成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=(10‑30)∶(10‑30)∶(9‑45)∶(9‑45)∶(10‑60)∶(8‑30)。本发明中药组合物可以在制备具有止咳和利尿功能的保健食品或药品中应用,其治疗效果好,安全可靠,而且采用岭南特色中药,原料易得。
Description
技术领域
本发明涉及医药领域,具体为一种含有积雪草的具有止咳和利尿功能的岭南特色中药组合物及其应用。
背景技术
积雪草,积雪草,中药名,为伞形科植物积雪草Centella asiatica(L.)Urb.的干燥全草。分布于西南及陕西、江苏、安徽、浙江、江西、福建、台湾、湖北、湖北、湖南、广东、广西等地。苦、辛,寒。具有清热利湿,解毒消肿之功效,常用于湿热黄疸,中暑腹泻,石淋血淋,痈肿疮毒,跌扑损伤。《神农本草经》:“主大热恶疮,痈疽,浸淫,赤熛,皮肤赤,身热。”《滇南本草》:“治子午潮热,眩晕,怕冷,肢体酸困,饮食无味,男妇童疳,虚劳发热不退者用之,利小便,水牛肉为引。”
现代研究证明,积雪草对小鼠、大鼠有镇静、安定作用,此作用主要是对中枢神经系统中的胆碱能系统的影响。积雪草甙能治疗皮肤溃疡,如顽固性创伤、皮肤结核、麻风等。对小鼠,豚鼠、兔肌肉注射或皮下植入可促进皮肤生长,局部白细胞增多、结缔组织盘管网增生、粘液分泌增加、毛及尾的生长加速等。积雪草醇提取物能松弛大鼠离体回肠。甙部分能降低家兔及大鼠离体回肠的张力及收缩幅度,并能轻度抑制乙酰胆碱的作用。对麻醉犬,静脉注射可轻度兴奋呼吸,心率变慢及中度的降低血压,后二者不能被阿托品阻断。有报道积雪甙对麻风病有治疗作用。
广东省地处热带与亚热带沿海地区,气候炎热,人们普遍嗜好生冷,部分人善饮酒好食烧烤,患者往往因过食生冷肥甘或恣意饮酒而影响脾胃的运化功能,导致水液不化,易聚而成湿,停而为痰。而烧烤食物和酒均多辛辣且大热容易湿热夹杂致痰多咳嗽,另外,湿性重浊粘滞,多阻遏气机,导致水湿内停,主要症状有小便不利、水肿等。利用岭南中药资源,开发止咳利尿的中药组合物具有重要意义。
发明内容
本发明的目的在于提供一种含有积雪草的中药组合物,其具有止咳和利尿功能,疗效明显且药性温和。
为了实现上述目的,本发明采用如下技术方案:一种含有积雪草的中药组合物,配方由以下重量比的中药材组成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=(10-30)∶(10-30)∶(9-45)∶(9-45)∶(10-60)∶(8-30)。
优选的,配方由以下重量比的中药材组成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=(15-30)∶(15-25)∶(9-30)∶(9-30)∶(15-60)∶(8-20)。
更优选的,配方由以下重量比的中药材组成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=20∶15∶15∶15∶20∶10。
上述中药组合物在制备具有止咳和利尿功能的保健食品或药品中的应用。
所述的保健食品或药品的剂型为汤剂、片剂、胶囊剂、颗粒剂、口服液或滴丸剂。
所述的保健食品或药品,是以所述中药组合物配方中组分的提取物为有效成分,添加药用辅料制得的制剂。
所述提取物为水提物。
本发明提供的岭南特色中药组合物具有止咳利尿的功效,其治疗效果好,安全可靠,而且采用岭南特色中药,原料易得。
具体实施方式
本发明是一种含有积雪草的具有止咳和利尿功能的岭南特色中药组合物,由以下重量比的中药材配制而成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=(10-30)∶(10-30)∶(9-45)∶(9-45)∶(10-60)∶(8-30)。优选的,由以下重量比的中药材配制而成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=(15-30)∶(15-25)∶(9-30)∶(9-30)∶(15-60)∶(8-20)。更优选的,由以下重量比的中药材配制而成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=20∶15∶15∶15∶20∶10。
本发明所使用的岭南特色中药中:
方中积雪草清热利湿,解毒消肿;鱼腥草清热解毒,利尿消肿共为君药。白茅根甘,寒,归肺、胃、膀胱经,凉血止血,清热利尿;车前草味甘,性寒,清热,利尿,祛痰,凉血,解毒;金钱草清利湿热,通淋,消肿。三药共为佐药。凉粉草味甘,淡,性寒,清暑,解渴,除热毒,为使药。
积雪草,为伞形科植物积雪草Centella asiatica(L.)Urb.的干燥全草。苦、辛,寒。具有清热利湿,解毒消肿之功效,常用于湿热黄疸,中暑腹泻,石淋血淋,痈肿疮毒,跌扑损伤。《神农本草经》:“主大热恶疮,痈疽,浸淫,赤熛,皮肤赤,身热。”
鱼腥草(英文名HERBA HOUTTUYNIAE)是中国药典收录的草药,草药来源为三白草科植物蕺菜(拉丁学名:Houttuynia cordata Thunb.)的干燥地上部分。鱼腥草味辛,性寒凉,归肺经。清热解毒,利尿消肿。治肺炎,肺脓疡,热痢,疟疾,水肿,淋病,白带,痈肿,痔疮,脱肛,湿疹,秃疮,疥癣。唐苏颂说:“生湿地,山谷阴处亦能蔓生,叶如荞麦而肥,茎紫赤色,江左人好生食,关中谓之菹菜,叶有腥气,故俗称:鱼腥草。”《滇南本草》:治肺痈咳嗽带脓血,痰有腥臭,大肠热毒,疗痔疮。《分类草药性》:治五淋,消水肿,去食积,补虚弱,消膨胀。
白茅根,为禾本科植物白茅Imperata cylindrica Beauv.var.major(Nees)C.E.Hubb.的干燥根茎。甘,寒。归肺、胃、膀胱经。凉血止血,清热利尿。用于血热吐血,衄血,尿血,热病烦渴,肺热咳嗽,胃热呕吐,湿热黄疸,水肿尿少,热淋涩痛。《本草纲目》:止吐衄诸血,伤寒哕逆,肺热喘急,水肿黄胆,解酒毒。《本草正义》:白茅根,寒凉而味甚甘,能清血分之热,而不伤干燥,又不粘腻,故凉血而不虑其积瘀,以主吐衄呕血。泄降火逆,其效甚捷,故又主胃火哕逆呕吐,肺热气逆喘满。又通利小水,泄热结之水肿,导瘀热之黄疸,皆甘寒通泄之实效。然其甘寒之力,清泄肺胃,尤有专长,凡齿痛龈肿,牙疳口舌诸疮,及肺热郁窒之咽痛腐烂诸证,用以佐使,功效最著,而无流弊。
车前草,为车前科植物车前Plantago asiatica L.或平车前PlantagodepressaWilld.的干燥或新鲜全草。味甘,性寒。归肝、肾、膀胱经。清热,利尿,祛痰,凉血,解毒。用于水肿尿少,热淋涩痛,暑湿泻痢,痰热咳嗽,吐血衄血,痈肿疮毒。《本草纲目》:王旻《山居录》,有种车前剪苗食法,则昔人常以为蔬矣。今野人犹采食之。《药性沦》:能去风毒,肝中风热,毒风冲眼目,赤痛障翳,脑痛泪出,去心胸烦热。《本草汇言》:车前子,行肝疏肾,畅郁和阳,同清热药用,止痢疾火郁。《药品化义》:车前子,子主下降,味淡入脾,渗热下行,主治痰泻、热泻,胸膈烦热,周身湿痹,盖水道利则清浊分,脾斯健矣。取其味淡性滑,滑可去暑,淡能渗热,用入肝经,又治暴赤眼痛,泪出脑疼,翳癃障目及尿管涩痛,遗精溺血,癃闭淋沥,下疳便毒,女人阴癃作痛、或发肿痒,凡此俱属肝热,导热下行,则浊自清矣。
金钱草,为报春花科植物过路黄Lysimachia christinae Hance的干燥全草。甘、咸,微寒。归肝、胆、肾、膀胱经。清利湿热,通淋,消肿。用于热淋,沙淋,尿涩作痛,黄疸尿赤,痈肿疔疮,毒蛇咬伤;肝胆结石,尿路结石。《现代实用中药》:"解热,镇咳,止渴,止血,利尿。治小儿痫热,疳病,瘰疬;研汁点暴赤眼;以盐揉贴肿毒并风癣。"《本草求原》:"祛风湿,止骨痛。浸酒舒筋活络,止跌打闪伤(痛),取汁调酒更效。"
凉粉草,为唇形科凉粉草属植物凉粉草Mesona chinensis Benth.的全草。味甘;淡;性寒。清暑,解渴,除热毒。治中暑,消渴,高血压,肌肉、关节疼痛。《中国药植图鉴》:"为清凉解渴除暑剂。全草煎服,治糖尿病。"《本草求原》:"清暑热,解藏府结热毒,治酒风。"
本发明所述的岭南特色中药组合物在制备具有止咳和利尿功能的保健食品或药品中的应用。保健食品或药品的剂型为汤剂,或者是以所述中药组合物配方中组分的提取物为有效成分,添加药用辅料制得的制剂,剂型可以为片剂、胶囊剂、颗粒剂、口服液或滴丸剂等。配方中组分提取物优选为水提物,采用一般的水提工艺制得。
下面结合实施例对本发明作进一步的说明,但本发明并不限于此特定例子。
实施例1
取积雪草20g、鱼腥草15g、白茅根15g、车前草15g、金钱草20g、凉粉草10g,加12倍量水,浸泡30分钟,回流提取1.5小时,提取2次,过滤,合并滤液,浓缩到100ml,得到汤剂。
实施例2
取积雪草30g、鱼腥草10g、白茅根9g、车前草45g、金钱草10g、凉粉草30g,加12倍量水,浸泡30分钟,回流提取1.5小时,提取2次,过滤,合并滤液,浓缩到120ml,得到汤剂。
实施例3
取积雪草10g、鱼腥草30g、白茅根45g、车前草9g、金钱草60g、凉粉草30g,加12倍量水,浸泡30分钟,回流提取1.5小时,提取2次,过滤,合并滤液,浓缩到150ml,得到汤剂。
实施例4
取积雪草20g、鱼腥草18g、白茅根30g、车前草20g、金钱草16g、凉粉草12g,加12倍量水,浸泡30分钟,回流提取1.5小时,提取2次,过滤,合并滤液,浓缩到100ml,得到汤剂。
实施例5
取上述实施例1所得汤剂,浓缩,干燥,得到干浸膏;取干浸膏14.6g,研成细粉,加入适量的药用淀粉和微粉硅胶,混合,过14目筛进行制粒,65℃干燥,再过14目筛进行整粒,然后加入适量的硬脂酸镁,混匀,压制成100片,即得片剂。每片重0.35g。
实施例6
取上述实施例1所得汤剂,浓缩,干燥,得到干浸膏;取干浸膏12.0g,研成细粉,与适量的磷酸氢钙、微晶纤维素、三氯蔗糖、交联聚维酮和羧甲基淀粉钠,混匀,3%聚维酮溶液为粘合剂,过14目筛进行制粒,65℃干燥,再过14目筛进行整粒,然后加入适量的硬脂酸镁,压制成100片,即得分散片。分散片每片0.35g。
实施例7
取上述实施例1所得汤剂,浓缩,干燥,得到干浸膏;取干浸膏12.8g,研成细粉,加入适量的药用淀粉和硬脂酸镁,混合均匀,过筛,装入胶囊,制成100粒,即得硬胶囊。每粒内容物重0.2g。
实施例8
取上述实施例1所得汤剂,浓缩,干燥,得到干浸膏;取干浸膏13.0g,加入适量的丙二醇、卵磷脂和大豆油,振动磨超微20分钟,使混匀,制成软胶囊100粒,即得软胶囊。每粒含内容物0.28g。
实施例9
取上述实施例1所得汤剂,浓缩,干燥,得到干浸膏;取干浸膏13.5g,研成细粉,加入适量的糊精和乳糖,混匀,制粒,65℃干燥,过14目筛进行整粒,分装,制得100包,即得颗粒剂。每包重3.5g。
实施例10
取上述实施例1所得汤剂,加入适量纯净水,搅拌加热煮沸,煮沸20分钟,待冷却到30-40℃时,加入适量壳聚糖和山梨酸钾,搅拌使溶解均匀,过滤,最后加纯净水调整至750ml,过滤,分装,灭菌,即得口服液。每支口服液10ml。
实验例1
1材料
SPF级KM小鼠,雄性,18-25g,由南方医科大学实验动物中心提供,动物合格证号:SCXK(粤)2011-2015]。本发明药物(按实施例1所制备汤剂,进行适当浓缩后给药),磷酸可待因(由南方医科大学附属中西医结合医院提供,15mg/片),复方金钱草颗粒(广西万通制药有限公司,批号:151019)。
2方法与结果
2.1止咳实验
2.1.1分组及给药
造模前需常规饲养小鼠三天;给药两天,实验前一天禁食不禁水12h,随机分成生理盐水空白组(8只)、磷酸可待因阳性对照组(0.5mg/ml)、本发明药物高/低剂量组等共4组,每组各8只。实验当天,每两只小鼠隔2min灌胃给药。给药后1小时,将两只小鼠放入经引咳装置,恒压喷浓氨水(28%)10s,记录小鼠咳嗽潜伏期(从开始喷雾到引起小鼠第1次咳嗽的时间)和3min内出现典型咳嗽的次数。3min内不咳者潜伏期以3min计,死亡者以咳嗽阳性计。典型咳嗽动作:腹肌收缩或缩胸,同时张大口,头微抬,有咳声。
数据处理用Prism统计软件,所有数据均用均数加减标准差表示,各组间比较用方差分析,q检验,均以P<0.05为有统计学差异,以P<0.01为有显著性差异。
2.1.2结果
结果见表1。
表1各组小鼠的咳嗽潜伏期和咳嗽次数(N=8)
注:与空白组相比,*p<0.05,**p<0.01。
表1说明,与空白对照组比较,本发明药物低、高剂量组在延长小白鼠咳嗽潜伏期方面均有效,但差异没有统计学意义(P>0.05);本发明药物高剂量组在减少小白鼠咳嗽次数方面有效,差异有统计学意义(P<0.05),阳性组在减少小白鼠咳嗽次数方面有明显统计学意义(P<0.01)。
2.2利尿实验
2.2.1分组及给药
造模前需常规饲养小鼠三天;给药两天,实验前一天禁食不禁水12h,随机分成生理盐水空白组、复方金钱草颗粒阳性对照组(0.39g/ml)、本发明药物高/低剂量组等共4组,每组各10只。实验前先轻压小鼠下腹,以排尽余尿,各组小鼠用1ml生理盐水腹腔注射作水负荷;半小时后灌胃给药。给药后立即将小鼠置于提前铺好可以覆盖底面的滤纸的代谢笼内,用电子天平记录每小时滤纸的增重量,连续观察5h,用作差法计算出每小时每只小鼠的排尿量。
数据处理用Prism统计软件,所有数据均用均数加减标准差表示,各组间比较用方差分析,q检验,均以P<0.05为有统计学差异,以P<0.01为有显著性差异。
2.2.2结果
结果见表2。表2说明5个小时尿量的产生阶段,空白组的尿量和时间呈线性关系,随着时间推移尿量逐渐下降,而阳性组、本发明药物高、低剂量组的尿量在第二小时内达到峰值,之后才逐渐降低,并且每个时间段内,阳性组和低剂量本发明药物组的排尿量均比空白组多,说明本发明药物具有利尿功效。
表2各组小鼠5小时内每小时的排尿量(单位:ml)(N=10)
注:与空白组相比,*p<0.05,**p<0.01。
Claims (6)
1.一种含有积雪草的中药组合物在制备具有止咳和利尿功能的药品中的应用,其特征在于:所述的中药组合物由以下重量比的中药材组成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=(10-30)∶(10-30)∶(9-45)∶(9-45)∶(10-60)∶(8-30)。
2.根据权利要求1所述的含有积雪草的中药组合物在制备具有止咳和利尿功能的药品中的应用,其特征在于:所述的中药组合物由以下重量比的中药材组成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=(15-30)∶(15-25)∶(9-30)∶(9-30)∶(15-60)∶(8-20)。
3.根据权利要求1所述的含有积雪草的中药组合物在制备具有止咳和利尿功能的药品中的应用,其特征在于:所述的中药组合物由以下重量比的中药材组成:积雪草∶鱼腥草∶白茅根∶车前草∶金钱草∶凉粉草=20∶15∶15∶15∶20∶10。
4.根据权利要求1所述的含有积雪草的中药组合物在制备具有止咳和利尿功能的药品中的应用,其特征在于:所述的药品的剂型为汤剂、片剂、胶囊剂、颗粒剂、口服液或滴丸剂。
5.根据权利要求1所述的含有积雪草的中药组合物在制备具有止咳和利尿功能的药品中的应用,其特征在于:所述的药品,是以所述中药组合物配方中组分的提取物为有效成分,添加药用辅料制得的制剂。
6.根据权利要求5所述的含有积雪草的中药组合物在制备具有止咳和利尿功能的药品中的应用,其特征在于:所述提取物为水提物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610553522.3A CN106075128B (zh) | 2016-07-12 | 2016-07-12 | 一种含有积雪草的中药组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610553522.3A CN106075128B (zh) | 2016-07-12 | 2016-07-12 | 一种含有积雪草的中药组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106075128A CN106075128A (zh) | 2016-11-09 |
CN106075128B true CN106075128B (zh) | 2019-10-01 |
Family
ID=57220204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610553522.3A Active CN106075128B (zh) | 2016-07-12 | 2016-07-12 | 一种含有积雪草的中药组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106075128B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103751583A (zh) * | 2013-12-30 | 2014-04-30 | 广西梧州制药(集团)股份有限公司 | 一种利尿保肝的中药组合物及其制备方法 |
CN104689259A (zh) * | 2015-04-02 | 2015-06-10 | 淄博夸克医药技术有限公司 | 一种用于治疗尿路感染的中药 |
CN105250769A (zh) * | 2015-11-04 | 2016-01-20 | 安徽益健堂中药饮片科技有限公司 | 一种治疗小儿肾炎、肾病的中药组合物 |
-
2016
- 2016-07-12 CN CN201610553522.3A patent/CN106075128B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103751583A (zh) * | 2013-12-30 | 2014-04-30 | 广西梧州制药(集团)股份有限公司 | 一种利尿保肝的中药组合物及其制备方法 |
CN104689259A (zh) * | 2015-04-02 | 2015-06-10 | 淄博夸克医药技术有限公司 | 一种用于治疗尿路感染的中药 |
CN105250769A (zh) * | 2015-11-04 | 2016-01-20 | 安徽益健堂中药饮片科技有限公司 | 一种治疗小儿肾炎、肾病的中药组合物 |
Non-Patent Citations (1)
Title |
---|
五草一根汤治疗急性肾小球肾炎47例小结;邓瑞锋等;《湖南中医杂志》;19910302(第1期);第28页右栏倒数第4段,第29页右栏第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN106075128A (zh) | 2016-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520578B (zh) | 一种治疗口腔溃疡的中药组合物及其制备方法 | |
CN103417911B (zh) | 化疗辅助用中药组合物 | |
CN106075128B (zh) | 一种含有积雪草的中药组合物及其应用 | |
CN101342331B (zh) | 治疗肺炎和上呼吸道感染的中药喷剂 | |
CN108419869A (zh) | 一种清热排毒下火的组合物、饮料及其制备方法 | |
CN104814221B (zh) | 一种罗汉果和金银花的茶饮料 | |
CN105435190A (zh) | 用于治疗寒热错杂型哮病的中药组合物及其制备方法 | |
CN104435247A (zh) | 治疗消化不良的药物组合物 | |
CN104353043A (zh) | 一种治疗五更泻的中药组合物及其制备方法 | |
CN105168425B (zh) | 一种提高免疫力的中药制剂及其制备方法 | |
CN103920042A (zh) | 用于治疗热陷营血型病毒性脑膜炎的药物及其制备方法 | |
CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN102755467B (zh) | 一种治疗冻伤的罗沙冬油膏及其制备方法 | |
CN105796748A (zh) | 一种治疗小儿惊厥的药物及制备方法 | |
CN105362993A (zh) | 治疗鹦鹉鱼白点病的酊剂及其制备方法 | |
CN103960432A (zh) | 一种控制高血压的中药茶饮 | |
CN104474440A (zh) | 用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 | |
CN103830611B (zh) | 一种治疗麻毒陷肺证型肺炎的中药 | |
CN103933427A (zh) | 用于治疗结节性霉素疹的药物组合物及其制备方法 | |
CN102940869B (zh) | 一种治疗猪腹泻的中药组合物 | |
CN103784587A (zh) | 一种治疗马皮肤病的药物组合 | |
CN113876836A (zh) | 一种小儿外用泡脚的中药组合物及其制备方法 | |
CN109430558A (zh) | 治疗猪阻塞性肺气肿的饲料添加剂及制备方法 | |
CN108967729A (zh) | 一种防治鸡马立克氏病的饲料添加剂及其制备方法 | |
CN107343930A (zh) | 一种治疗失音的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |